Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease entities : Sanofi save search
FDA Approves First Gene Therapy for Rare Pediatric Disease
Published: 2024-03-18 (Crawled : 23:00) - biospace.com/
PRGO | $31.23 2.43% 0.0% 960K
|
Health Technology
|
| O: 0.33%
H: 0.13%
C: -1.51%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.2%
H: 0.08%
C: -1.14%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: 1.71%
H: 0.36%
C: -2.52%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.81%
H: 0.0%
C: 0.0%
fda rare first disease therapy
Incyte Gets Phase II Win, Targets Blockbuster Dupixent in Skin Disease
Published: 2024-03-11 (Crawled : 16:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
disease dupixent skin
Rare Disease Drug Development Urgently Needs More Funding, Experts Say
Published: 2024-02-29 (Crawled : 06:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.6%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
rare drug disease
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
Published: 2024-02-24 (Crawled : 16:20) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
disease urticaria results
Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA
Published: 2024-02-20 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 2.72%
H: 0.0%
C: -0.8%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 2.53%
H: 0.0%
C: 0.0%
ibi311 disease thyroid eye trial
Hydroxychloroquine Market to Reach $2.86 Billion by 2028 Amidst Rising Demand for Autoimmune Disease Treatments
Published: 2024-02-13 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -2.71%
H: 0.0%
C: 0.0%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.02%
H: 0.24%
C: 0.01%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
disease reach market
Listeria Monocytogenes Infections Treatment Global Market Report 2024: Global Expansion in Listeria Monocytogenes Treatment Sector Predicted Amid Rising Foodborne Disease Incidence
Published: 2024-02-14 (Crawled : 00:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: -2.14%
H: 0.0%
C: -0.63%
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -2.71%
H: 0.0%
C: 0.0%
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 0.87%
H: 0.21%
C: -2.23%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 0.89%
H: 0.41%
C: 0.1%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.38%
H: 2.44%
C: 1.54%
VRTX | $400.66 -1.05% -1.06% 810K
|
Health Technology
|
| O: 0.56%
H: 0.49%
C: -0.12%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 0.16%
H: 0.43%
C: -2.76%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 0.28%
H: 0.93%
C: 0.75%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.21%
H: 0.34%
C: 0.07%
disease report treatment expansion global infections market
Animal Therapeutics and Diagnostics Global Market Report 2024 - Dermatological Disease Management in Animals to Propel Market Growth
Published: 2024-02-13 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -2.71%
H: 0.0%
C: 0.0%
ZTS | $150.88 0.88% -0.5% 3.6M
|
Health Technology
|
| O: 0.93%
H: 0.7%
C: -0.6%
TMO | News | $577.39 0.49% 0.0% 2M
|
Health Technology
|
| O: 0.56%
H: 1.3%
C: 1.22%
QGEN | $41.52 -0.88% 0.0% 820K
|
Health Technology
|
| O: -1.14%
H: 1.3%
C: 1.2%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.38%
H: 2.44%
C: 1.54%
ELAN | $13.31 -1.11% 0.0% 3.8M
|
Process Industries
|
| O: 1.53%
H: 1.16%
C: 0.82%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
QGEN | $41.52 -0.88% 0.0% 820K
|
Health Technology
|
| O: -1.14%
H: 1.3%
C: 1.2%
PAHC | $12.575 -7.61% -8.23% 110K
|
Health Technology
|
| O: 1.32%
H: 4.7%
C: 4.09%
NEOG 4 | $12.375 0.53% 0.53% 2.5M
|
Health Technology
|
| O: -0.24%
H: 4.39%
C: 3.29%
management propel disease report animal global animals dermatological diagnostics therapeutics growth market
Liver Disease Therapeutics Competitive Landscape and Market Forecasts to 2028
Published: 2024-02-12 (Crawled : 20:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 0.37%
H: 0.74%
C: 0.28%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.18%
H: 0.48%
C: -1.91%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.32%
H: 0.11%
C: -1.55%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -2.63%
H: 0.98%
C: -1.75%
liver disease therapeutics market
Global Pompe Disease Drugs Market: USD 294.7 Million Growth Forecasted at a CAGR of 4.16% between 2024 to 2028 - Technavio
Published: 2024-01-26 (Crawled : 00:20) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
ALPMF | News | $9.5 43.47% 1.2K
|
Health Technology
| Email alert
Add to watchlist
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
| Email alert
Add to watchlist
disease million global growth
Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
Published: 2024-01-23 (Crawled : 07:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -2.05%
H: 0.0%
C: 0.0%
INBX | $34.385 0.75% 0.74% 220K
|
Health Technology
|
| O: 6.51%
H: 4.73%
C: 2.25%
rare disease pipeline acquire potential sanofi
Global Respiratory Disease Vaccine Market Set for Growth, Fueled by Aging Populations and Vaccine Mandates - Trends, Opportunities, and Forecasts, 2018-2028F
Published: 2024-01-22 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 1.71%
H: 0.0%
C: -0.15%
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 2.63%
H: 0.8%
C: 0.75%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.6%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.21%
H: 0.0%
C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 1.8%
H: 0.14%
C: -0.89%
disease vaccine respiratory global set market
Chronic Disease Markets for Sustained Released Injectables: The Trend toward Self-Administration
Published: 2024-01-15 (Crawled : 12:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
disease
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
Published: 2024-01-09 (Crawled : 16:00) - biospace.com/
SKYE | $12.845 -8.45% -9.23% 110K
|
Transportation and Warehousing
|
| O: -7.02%
H: 29.11%
C: 15.56%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
obesity disease kidney bioscience clearance trial
Sanofi Drops Acquisition of Maze’s Pompe Disease Drug After FTC Challenge
Published: 2023-12-12 (Crawled : 14:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.43%
H: 0.0%
C: 0.0%
drug disease acquisition sanofi
Maze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001, a Potential Oral Substrate Reduction Therapy for Pompe Disease
Published: 2023-12-11 (Crawled : 00:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.5%
H: 1.67%
C: 0.1%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 2.15%
H: 0.0%
C: 0.0%
mze001 disease license collaboration therapeutics potential agreement therapy sanofi
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone
Published: 2023-12-11 (Crawled : 01:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.5%
H: 1.67%
C: 0.1%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 2.15%
H: 0.0%
C: 0.0%
sarclisa disease plus
Neuromuscular Disease Therapeutics Market size to grow by USD 65.13 billion from 2022-2027| Aquestive Therapeutics Inc., Bausch Health Companies Inc., Biogen Inc. and more among the major companies in the market- Technavio
Published: 2023-12-01 (Crawled : 19:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
| Email alert
Add to watchlist
BHC | $8.56 0.35% 0.0% 2M
|
Health Technology
| Email alert
Add to watchlist
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
| Email alert
Add to watchlist
BCLI A | $0.5339 1.7% 1.67% 190K
|
Health Technology
| Email alert
Add to watchlist
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
| Email alert
Add to watchlist
disease companies health therapeutics market
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: -0.52%
H: 3.73%
C: 1.87%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.09%
H: 0.0%
C: 0.0%
disease treatment collaboration teva deal
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.46%
H: 0.37%
C: -0.49%
dupixent fda disease approved positive copd potential submission
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.